Physician profile
John Wood
NPI 1538182811
$4,712.65
in general payments reported to CMS, 2019-2025
51 companies · $683 in 2025
The $683 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $357 · 2021: $835 · 2022: $803 · 2023: $641 · 2024: $710 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $577.77 | 2019-2024 | Saphnelo, Tezspire, Evusheld |
| Glaxosmithkline, LLC. | $502.22 | 2019-2025 | Nucala, Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.37 | 2019-2025 | Ofev, Cyltezo |
| Lilly USA, LLC | $281.56 | 2019-2025 | Taltz, Jardiance, Mounjaro |
| Genzyme Corporation | $258.18 | 2019-2025 | |
| Novo Nordisk INC | $206.45 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $161.55 | 2020-2024 | Evenity, Prolia, Tavneos |
| Mylan Specialty L.P. | $153.54 | 2019-2023 | Yupelri |
| Medtronic, INC. | $148.31 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbott Laboratories | $147.07 | 2021-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $140.15 | 2019-2025 | Dupixent |
| Janssen Biotech, INC. | $139.02 | 2019-2023 | Tremfya |
| Xeris Pharmaceuticals, INC. | $116.38 | 2020-2025 | Gvoke Hypopen, Keveyis, Recorlev |
| Recordati_rare_diseases_inc. | $112.54 | 2021-2025 | Isturisa, Signifor Lar |
| Sunovion Pharmaceuticals INC. | $104.51 | 2019 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.